Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (3347)	12/16/1997 7:12:00 PM
From: Juergen	Respond to of 6136

ALTAREX CORP., immunotherapeutic biotech company. Comparable to CNTO, CYTO, MEDX, CLTR, IDPH, PDLI, IMMU. Conducting Phase IIb pivotal trial for its ovarian cancer therapeutic vaccine Ovarex in the US, and Phase II/III in Europe and Canada.

To: Henry Niman who wrote (3347)	12/16/1997 7:20:00 PM
From: Izzy	Read Replies (1) \| Respond to of 6136

OFF TOPIC. Henry, it is my understanding that Kaposi's sarcoma (KS) is caused by human herpesvirus-8 (HHV-8), which is found in 100% of KS tissue. HHV-8 is found in sperm, semen, B lymphocytes, endothelial cells, saliva, nasal secretions, and respiratory fluid of patients with pulmonary KS. HHV-8 is most likely transmitted sexually. However, not all KS cases are cutaneous (skin). Interferon, liposome, and Taxol are some treatments. The retinoids apparently downregulate interleukin-6. So, how does the LGND gel work? And wouldn't it only be effective in localized cutaneous lesions? Certainly it could not be a treatment for all cases of KS, which can occur in HIV+ patients who do not have AIDS (similar to other HIV related malignancies, such as lymphomas). Please educate me. Thanks.